Role of KIT and platelet-derived growth factor receptors as oncoproteins

Seminars in Oncology

Volumn 31, Issue SUPPL. 6, 2004, Pages 4-11

  Fletcher, Jonathan A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

CLINICAL TRIAL; DRUG EFFICACY; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; WILD TYPE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STEM CELL FACTOR;

EID: 3042711783     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.03.034     Document Type: Article

References (45)

1. Heinrich M.C., Rubin B.P., Longley B.J., et al. Biology and genetic aspects of gastrointestinal stromal tumors KIT activation and cytogenetic alterations. Hum Pathol. 33:2002;484-495
2. Steer E.J., Cross N.C. Myeloproliferative disorders with translocations of chromosome 5q31-35 Role of the platelet-derived growth factor receptor Beta. Acta Haematol. 107:2002;113-122
3. Heldin C.H., Eriksson U., Östman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys. 398:2002;284-290
4. Buchdunger E., O'Reilly T., Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 38:(suppl 5):2002;S28-S36
5. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 38:(suppl 5):2002;S3-S10
6. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:2000;139-145
7. Capdeville R., Buchdunger E., Zimmermann J., et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 1:2002;493-502
8. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566
9. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037
10. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004
11. Heinrich M.C., Griffith D.J., Druker B.J., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932
12. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580
13. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710
14. Tuveson D.A., Fletcher J.A. Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol. 13:2001;249-255
15. Östman A., Heldin C.H. Involvement of platelet-derived growth factor in disease Development of specific antagonists. Adv Cancer Res. 80:2001;1-38
16. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours A phase I study. Lancet. 358:2001;1421-1423
17. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:2002;472-480
18. Pietras K., Sjöblom T., Rubin K., et al. PDGF receptors as cancer drug targets. Cancer Cell. 3:2003;439-443
19. Li H., Fredriksson L., Li X., et al. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 22:2003;1501-1510
20. Yu J., Ustach C., Kim H.R. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol. 36:2003;49-59
21. Shimizu A., O'Brien K.P., Sjöblom T., et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59:1999;3719-3723
22. Greco A., Roccato E., Miranda C., et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 92:2001;354-360
23. Sjöblom T., Shimizu A., O'Brien K.P., et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61:2001;5778-5783
24. Rubin B.P., Schuetze S.M., Eary J.F., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 20:2002;3586-3591
25. Maki R.G., Awan R.A., Dixon R.H., et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 100:2002;623-626
26. Fleming T.P., Saxena A., Clark W.C., et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52:1992;4550-4553
27. Guha A., Dashner K., Black P.M., et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 60:1995;168-173
28. Kilic T., Alberta J.A., Zdunek P.R., et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60:2000;5143-5150
29. Zhao J., Roth J., Bode-Lesniewska B., et al. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer. 34:2002;48-57
30. Cross N.C., Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia. 16:2002;1207-1212
31. Tomasson M.H., Sternberg D.W., Williams I.R., et al. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest. 105:2000;423-432
32. Baxter E.J., Hochhaus A., Bolufer P., et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 11:2002;1391-1397
33. Gleich G.J., Leiferman K.M., Pardanani A., et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 359:2002;1577-1578
34. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 348:2003;1201-1214
35. Magnusson M.K., Meade K.E., Nakamura R., et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 100:2002;1088-1091
36. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 347:2002;481-487
37. Kimura A., Nakata Y., Katoh O., et al. c-kit Point mutation in patients with myeloproliferative disorders. Leuk Lymphoma. 25:1997;281-287
38. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 156:2000;791-795
39. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121
40. Longley B.J., Reguera M.J., Ma Y. Classes of c-KIT activating mutations Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 25:2001;571-576
41. Heinrich M.C., Blanke C.D., Druker B.J., et al. Inhibition of KIT tyrosine kinase activity A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 20:2002;1692-1703
42. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 344:2001;1052-1056
43. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 99:2002;1741-1744
44. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 21:2003;4342-4349
45. Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 125:2003;660-667